



Department
of Health &
Social Care

**Vaccines and Therapeutics – Cabinet
Secretary Deep Dive
Thursday, 16th April**

We do not have sufficient vaccine manufacturing capacity

The UK Manufacturing Challenge

- ❖ Most vaccines in the UK have historically been developed by academic institutions and SMEs, who lack capability and capacity to manufacture at speed and scale. The need to manufacture future vaccines at greater speed and scale is why we are looking to secure the £70-93 million needed to fund the accelerated development of VMIC.
- ❖ Large pharma companies in the UK tend to focus on flu vaccines, where there is a regular demand so there is limited capacity for the key "fill and finish" stage.
- ❖ To make sure a vaccine can be deployed from the moment it is declared as effective and safe, we may need to manufacture at risk, i.e. produce millions of doses that may then prove to not work. We believe the social and economic benefits from developing a vaccine quickly outweigh the financial risk.
- ❖ The exact number of doses needed may be anything from 20 million (for healthcare workers and the vulnerable) to 70 million (the whole population). We won't know until we know more about the disease. It is possible the disease will also return annually.

We will need to invest in some manufactures in the next week (or at least offer assurance) or risk losing them. In the near future we will also have to invest in supply chains.

Short term (Now – summer)	<ul style="list-style-type: none"> Working with Oxford and Imperial to establish manufacturing requirements for clinical trialling. Establish UK supply chain pressures, so we have the materials we need for when we need them. Put together package for Moderna. 	<ul style="list-style-type: none"> Oxford clinical trials Phase 1 and 2 – funding agreed 12 April. Phase 3 – funding bid sent to Ministers 14 April. BIA to advise on Imperial's needs w/c 13 April. Funding bid to Ministers to follow w/c 20 April. Technical calls with Moderna led by BIA and DIT, incl 14 April.
Medium term (Now – Dec)	<ul style="list-style-type: none"> Ensure Oxford and Imperial's exact supply chain and fill and finish needs are understood now. Potentially start to manufacture at risk. 	<ul style="list-style-type: none"> Oxford business case agreed 11 April, including timelines. Initial funding bid sent to Ministers 14 April. BIA to advise on Imperial's needs w/c 13 April. Initial funding bid to Ministers follow w/c 20 April.
Long term (2021-)	<ul style="list-style-type: none"> Establish permanent capacity in the UK for future pandemics, including accelerating the build of the Vaccines Manufacturing & Innovation Centre. 	<ul style="list-style-type: none"> UKRI completed cost analysis of accelerating VMIC to June 2021 on 9 April. Funding bid sent to Ministers 14 April. Possible announcement 17 April.